ASCO 2019 | Future treatment options for squamous cell lung cancer

Paul Paik

Speaking from the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL, Paul Paik of the Memorial Sloan Kettering Cancer Center, New York, NY discusses future direction for squamous cell lung cancer treatment and the potential for immunotherapy.

Share this video  
Similar topics
Related videos
0:54
SB8: a bevacizumab biosimilar for NSCLC
Martin Reck
2:19
The immunotherapy NSCLC revolution
Solange Peters
1:40
ALK-positive NSCLC: CNS progression
Sanjay Popat
2:26
CheckMate 227 update
Sanjay Popat
1:49
SCLC hyperprogression with nivolumab
Martin Reck
Lung Cancer
ASCO 2019
Interview
3rd June 2019
More from Paul Paik
Patient impact: development of drugs to treat METex14 alterations
Squamous cell lung cancer: gene targets
Tepotinib: advanced non-small cell lung cancer
vjoncology logo VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals